egovy (semaglutide) is a powerful GLP-1 receptor agonist prescribed for chronic weight management, but certain individuals face significant risks and should not take it due to contraindications outlined in official prescribing information.

Core Contraindications

These groups are explicitly barred from using Wegovy to prevent severe health complications:

  • Patients with a personal or family history of medullary thyroid carcinoma (MTC) , as animal studies link semaglutide to thyroid C-cell tumors.
  • Those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) , a rare condition raising thyroid cancer risk.
  • Individuals with a prior serious hypersensitivity reaction to semaglutide or Wegovy's excipients, including anaphylaxis or angioedema.

High-Risk Precautions

Healthcare providers often advise against Wegovy—or require close monitoring—for these conditions, as side effects like nausea, vomiting, and dehydration can worsen them:

  • Severe gastrointestinal disorders : Including inflammatory bowel disease, gastroparesis, or severe GERD, since Wegovy delays gastric emptying.
  • Type 1 diabetes or history of diabetic retinopathy, due to risks of hypoglycemia or eye complications.
  • Severe renal or hepatic impairment : Limited data exists, and dehydration from GI side effects heightens kidney injury risk.
  • Pregnant or breastfeeding individuals : Potential fetal harm; discontinue at least 2 months before planning pregnancy.

Key Warnings Table

Condition| Why Avoid Wegovy| Alternative Considerations
---|---|---
MTC or MEN 2 History| Thyroid tumor risk 1| Lifestyle changes, other therapies
Hypersensitivity| Anaphylaxis/angioedema 1| Switch to non-semaglutide options
Severe GI Disease| Exacerbates symptoms 7| Surgical or behavioral interventions
Pregnancy/Breastfeeding| Fetal risks 4| Diet/exercise under medical guidance
Renal Impairment (Severe)| Dehydration worsens kidneys 7| Dose-adjusted alternatives

Real-World Insights & Trends

As of early 2026, forum discussions on platforms like Reddit highlight growing awareness of these restrictions amid Wegovy's popularity surge post-2025 shortages easing. Users share stories of doctors rejecting prescriptions for family thyroid histories, emphasizing genetic screening. Trending topics also note rising lawsuits over undisclosed risks, underscoring the need for full disclosure to providers. One viewpoint: While effective for obesity (15-20% weight loss in trials), safer profiles in non-contraindicated patients make it transformative—but never DIY.

Always consult a healthcare professional for personalized advice, as individual factors vary. TL;DR : Avoid Wegovy if you have MTC/MEN 2 history, hypersensitivity, or severe GI/kidney issues—prioritize doctor evaluation.

Information gathered from public forums or data available on the internet and portrayed here.